Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New siRNA drug aims to tame kidney disease

NCT ID NCT06989359

Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 04, 2026 · Updated 6 times

Summary

This Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe and can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ADX-038 (siRNA drug)
What this could lead to
If successful, this could lead to a new treatment option that helps control complement-mediated kidney diseases, potentially slowing disease progression and reducing symptoms.
What could go wrong
This is an early Phase 2 trial with only 45 participants, so results may not apply to everyone. The drug may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mean eGFR greater than or equal to 30 mL/min/1.73m2 * Clinical evidence of active kidney disease * Treated with supportive care including an ACE inhibitor or ARB if applicable * Willing to receive required vaccinations * Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy Exclusion Criteria: * Hereditary or acquired complement deficiency * Kidney transplant or renal replacement therapy * History of solid organ transplant * Other kidney disease * History of recurrent invasive infections * Received complement inhibitor treatments * Active systemic viral, bacterial, or fungal infection * Abnormal liver function

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3G are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

C3 glomerulonephritis complement 3 glomerulopathy IgA glomerulonephritis IgA nephropathy, susceptibility to, 1 immunoglobulin-mediated membranoproliferative glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3G Complement-mediated kidney disease Ic-MPGN IgA nephropathy (IGAN) IGAN

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    35 sites in 8 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • ADARx Clinical Site

    WITHDRAWN

    Doral, Florida, 33122, United States

  • ADARx Clinical Site

    RECRUITING

    Miami, Florida, 33127, United States

  • ADARx Clinical Site

    WITHDRAWN

    Pembroke Pines, Florida, 33029, United States

  • ADARx Clinical Site

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • ADARx Clinical Site

    RECRUITING

    Shreveport, Louisiana, 71101, United States

  • ADARx Clinical Site

    RECRUITING

    Shelby, Michigan, 48315, United States

  • ADARx Clinical Site

    RECRUITING

    Great Neck, New York, 11021, United States

  • ADARx Clinical Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • ADARx Clinical Site

    RECRUITING

    Dakota Dunes, South Dakota, 57049, United States

  • ADARx Clinical Site

    WITHDRAWN

    Dallas, Texas, 75230, United States

  • ADARx Clinical Site

    RECRUITING

    Houston, Texas, 77027, United States

  • ADARx Clinical Site

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

  • ADARx Clinical Site

    RECRUITING

    Wollongong, New South Wales, 2500, Australia

  • ADARx Clinical Site

    RECRUITING

    Sydney, NSW 2139, Australia

  • ADARx Clinical Site

    RECRUITING

    Woolloongabba, QLD 4102, Australia

  • ADARx Clinical Site

    RECRUITING

    Hong Kong, 2500, Hong Kong

  • ADARx Clinical Site

    RECRUITING

    Shatin, Hong Kong

  • ADARx Clinical Site

    RECRUITING

    Bergamo, 24020, Italy

  • ADARx Clinical Site

    NOT_YET_RECRUITING

    Bologna, 40138, Italy

  • ADARx Clinical Site

    RECRUITING

    Pavia, 27100, Italy

  • ADARx Clinical Site

    RECRUITING

    Wŏnju, Gangwon-do, 26426, South Korea

  • ADARx Clinical Site

    RECRUITING

    Gyeonggi-do, Gurogu, 16499, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, Gurogu, 08308, South Korea

  • ADARx Clinical Site

    RECRUITING

    Cheonan, 31151, South Korea

  • ADARx Clinical Site

    RECRUITING

    Daegu, 42601, South Korea

  • ADARx Clinical Site

    RECRUITING

    Gyeonggi-do, 05278, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, 02841, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, 03080, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, 03722, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, 05278, South Korea

  • ADARx Clinical Site

    RECRUITING

    Barcelona, 08035, Spain

  • ADARx Clinical Site

    RECRUITING

    Madrid, 28040, Spain

  • ADARx Clinical Site

    RECRUITING

    Madrid, 28041, Spain

  • ADARx Clinical Site

    RECRUITING

    Seville, 41009, Spain

  • ADARx Clinical Site

    NOT_YET_RECRUITING

    Kaohsiung City, 833401, Taiwan

  • ADARx Clinical Site

    RECRUITING

    New Taipei City, 110, Taiwan

  • ADARx Clinical Site

    RECRUITING

    Leicester, BC, LE5 4PW, United Kingdom

  • ADARx Clinical Site

    RECRUITING

    Newcastle upon Tyne, UK, NE7 7DN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.